Navellier & Associates Inc Harmony Biosciences Holdings, Inc. Transaction History

Navellier & Associates Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$30.5 - $37.4 $7,594 - $9,312	-249 Reduced 3.99%	5,992 $210,000
Q1 2023 May 12, 2023	SELL	$30.8 - $53.92 $5,297 - $9,274	-172 Reduced 2.68%	6,241 $203,000
Q4 2022 Feb 02, 2023	SELL	$45.4 - $60.91 $27,830 - $37,337	-613 Reduced 8.72%	6,413 $353,000
Q3 2022 Nov 09, 2022	BUY	$42.06 - $55.45 $295,513 - $389,591	7,026 New	7,026 $311,000

247

45.5M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.25B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.